These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 17503103)

  • 1. Angiotensin receptor blockers on the formularies of Medicare drug plans.
    Gellad WF; Huskamp HA; Phillips KA; Haas JS
    J Gen Intern Med; 2007 Aug; 22(8):1172-5. PubMed ID: 17503103
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of a step-therapy program for angiotensin receptor blockers on antihypertensive medication utilization patterns and cost of drug therapy.
    Yokoyama K; Yang W; Preblick R; Frech-Tamas F
    J Manag Care Pharm; 2007 Apr; 13(3):235-44. PubMed ID: 17407390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identifying widely covered drugs and drug coverage variation among Medicare part D formularies.
    Tseng CW; Mangione CM; Brook RH; Keeler E; Dudley RA
    JAMA; 2007 Jun; 297(23):2596-602. PubMed ID: 17579228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The formulary files. ARB costs run high in Medicare part D.
    Manag Care; 2007 Aug; 16(8):48. PubMed ID: 17886540
    [No Abstract]   [Full Text] [Related]  

  • 5. Prescription Drug Spending and Medication Adherence Among Medicare Beneficiaries with Heart Failure.
    McGee BT; Phillips V; Higgins MK; Butler J
    J Manag Care Spec Pharm; 2019 Jun; 25(6):705-713. PubMed ID: 31134861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of Medicare Part D on medication treatment of hypertension.
    Zhang Y; Donohue JM; Lave JR; Gellad WF
    Health Serv Res; 2011 Feb; 46(1 Pt 1):185-98. PubMed ID: 20880045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coverage for high-cost specialty drugs for rheumatoid arthritis in Medicare Part D.
    Yazdany J; Dudley RA; Chen R; Lin GA; Tseng CW
    Arthritis Rheumatol; 2015 Jun; 67(6):1474-80. PubMed ID: 25900105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship of the magnitude of member cost-share and medication persistence with newly initiated renin angiotensin system blockers.
    Zhang D; Carlson AM; Gleason PP; Schondelmeyer SW; Schommer JC; Dowd BE; Heaton AH
    J Manag Care Pharm; 2007 Oct; 13(8):664-76. PubMed ID: 17970604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How does drug coverage vary by insurance type? Analysis of drug formularies in the United States.
    Régnier SA
    Am J Manag Care; 2014 Apr; 20(4):322-31. PubMed ID: 24884863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of cost sharing on prescription drugs used by Medicare beneficiaries.
    Goedken AM; Urmie JM; Farris KB; Doucette WR
    Res Social Adm Pharm; 2010 Jun; 6(2):100-9. PubMed ID: 20511109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of incentive-based formularies on prescription-drug utilization and spending.
    Huskamp HA; Deverka PA; Epstein AM; Epstein RS; McGuigan KA; Frank RG
    N Engl J Med; 2003 Dec; 349(23):2224-32. PubMed ID: 14657430
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonadherence to angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers among high-risk patients with diabetes in Medicare Part D programs.
    Yang Y; Thumula V; Pace PF; Banahan BF; Wilkin NE; Lobb WB
    J Am Pharm Assoc (2003); 2010; 50(4):527-31. PubMed ID: 20621872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Should Medicare adopt the Veterans Health Administration formulary?
    Frakt AB; Pizer SD; Feldman R
    Health Econ; 2012 May; 21(5):485-95. PubMed ID: 21506191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost variability of suggested generic treatment alternatives under the Medicare Part D benefit.
    Patel RA; Walberg MP; Tong E; Tan F; Rummel AE; Woelfel JA; Carr-Lopez SM; Galal SM
    J Manag Care Spec Pharm; 2014 Mar; 20(3):283-90. PubMed ID: 24564812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trends in the prescription drug plans delivering the Medicare Part D prescription drug benefit.
    Brill JV
    Am J Health Syst Pharm; 2007 Aug; 64(15 Suppl 10):S3-6; quiz S21-S23. PubMed ID: 17646551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A bitter pill: formulary variability and the challenge to prescribing physicians.
    Shrank WH; Ettner SL; Glassman P; Asch SM
    J Am Board Fam Pract; 2004; 17(6):401-7. PubMed ID: 15575031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The nuts and bolts of PDPs.
    Stahlman ME
    Issue Brief George Wash Univ Natl Health Policy Forum; 2006 Nov; (817):1-18. PubMed ID: 17099987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Access to cancer drugs in Medicare Part D: formulary placement and beneficiary cost sharing in 2006.
    Bowman J; Rousseau A; Silk D; Harrison C
    Health Aff (Millwood); 2006; 25(5):1240-8. PubMed ID: 16966719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Variation in estimated Medicare prescription drug plan costs and affordability for beneficiaries living in different states.
    Davis MM; Patel MS; Halasyamani LK
    J Gen Intern Med; 2007 Feb; 22(2):257-63. PubMed ID: 17356996
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug benefit generosity and essential medication use among Medicare-eligible retirees.
    Doshi JA; Polsky D
    Am J Manag Care; 2007 Jul; 13(7):425-31. PubMed ID: 17620038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.